Werewolf Therapeutics (HOWL): which funds own it

Who owns Werewolf Therapeutics?

Holders reporting more than 5% of the shares to the SEC (Schedules 13D/13G): Moll Peter, 5.2% (13G filed Sep 21, 2026). Ra Capital Management, L.P., Kolchinsky Peter and UBS Oncology Impact Fund L.P. are listed on their Form 4 filings as owners of more than 10%. As of Jun 30, 2026, the largest holders reported on Form 13F were RA Capital Management (4.9% of the shares), Balyasny Asset Management (3.7%) and Vanguard Capital Management (2.5%).

Sources:13G by Moll Peter (Sep 21, 2026) ↗All of the company's proxy statements on EDGAR ↗

13F percentages divide the shares each institution reports by the shares outstanding on the cover of the company's latest report before the quarter end (May 1, 2026). Entities of the same group file separately and are not added up. We hold 13D and 13G filings made since Dec 23, 2024: a holder above 5% that has not filed since then does not appear here.

• RA Capital Managementconcentrated2.4 MInvestment firm · 4.91% of the company−4.3 M
• Balyasny Asset Management1.8 MQuant or multi-manager · 3.68% of the company+1.8 M
• Vanguard Capital Management1.2 MIndex manager · 2.51% of the company0
• Renaissance Technologies675 KQuant or multi-manager · 1.39% of the company+158 K
• Lynx1 Capital Managementconcentrated658 KInvestment firm · 1.35% of the company0
• Sphera Funds Management627 KInvestment firm · 1.29% of the company0
• DC Funds589 KType not verified · 1.21% of the company0
• Verdad Advisers349 KType not verified · 0.72% of the company+319 K
• Geode Capital Management336 KIndex manager · 0.69% of the company−54 K
• Bank of America312 KBank or trading desk · 0.64% of the company+47 K

The 10 13F filers with the most shares as of Jun 30, 2026, whatever their type (index firms usually come first). “Change”: shares added or cut versus the previous quarter, split-adjusted; “no data” = there is no comparable portfolio for the previous quarter (no filing, or a filing with its holdings under confidential treatment). “% of the company” only where shares outstanding are up to date. Entities of the same group file separately and some 13F filings include other managers: there may be double counting. With a free account: the top 25, the largest buyers and the largest sellers.

Held by institutions (13F)

Institutions (13F): 22.4% of the shares · top 10: 18.4% · in index firms: 18.6% of the institutional total

Shares reported by the 45 13F filers as of Jun 30, 2026, divided by the shares outstanding on the cover of the company's latest report (May 1, 2026). It is not all institutional ownership: only managers above $100M file a 13F, and it excludes short positions. Entities of the same group file separately and some 13F filings include other managers: there may be double counting. We only publish it where the figure is credible: not for ADRs, companies with more than one share class or stale shares-outstanding data.

Shares outstanding: buybacks and dilution

From the statements the company filed with the SEC (10-K). The change compares average diluted shares of each fiscal year, on today's basis: negative = it bought back more than it issued; positive = dilution. “No data” = the company does not report that item under a tag we can read; it does not mean zero.

Earnings quality and debt

From the figures the company filed with the SEC. Cash flow over net income near or above 1 means earnings are collected in cash; far below, that part is accounting. Coverage says how many times operating income pays the latest fiscal year's interest. Maturities come from the debt note of the latest annual report, counted from its closing date. “No data” never means zero.

Above 5% over time (13D/13G)

Each holder with its filings in order. History since December 2024.

Flagged material events (8-K)

• Feb 6, 2026Seriousfiling ↗

  Notice of delisting or failure to meet a listing rule (Item 3.01)

• Feb 13, 2026Mediumfiling ↗

  Exit or restructuring costs (Item 2.05)

• Aug 21, 2026Routinefiling ↗

  Unregistered sale of equity securities (Item 3.02)

  «Werewolf Therapeutics and Ambros Therapeutics Announce Merger Agreement and Concurrent Oversubscribed $150 million Private Placement»

• Feb 13, 2026Routinefiling ↗

  Change in directors or officers (Item 5.02)

Alert items the company itself flagged in its 8-K filings with the SEC, most serious first. It is the form's label, with no interpretation from us: Item 5.02 covers routine appointments as well as a chief executive's departure; open the filing. The quoted headline is the original press release's.